Dr. Reddy's Laboratories has launched Obeda, a generic semaglutide injection for Type 2 diabetes, becoming the first Indian company to receive DCGI approval for this GLP-1 receptor agonist. Available in 2mg and 4mg strengths, the once-weekly subcutaneous injection demonstrated non-inferior efficacy and a comparable safety profile in Phase III studies.